B-cell lymphoma 2 messenger RNA (BCL2 mRNA)

Human B-cell lymphoma 2 (BCL2) mRNA is the transcript of the BCL2 gene (NCBI Gene ID: 596), which encodes a key anti-apoptotic protein that prevents programmed cell death by inhibiting mitochondrial outer membrane permeabilization (UniProt: P10415). In many hematologic malignancies, such as follicular lymphoma and chronic lymphocytic leukemia, BCL2 is overexpressed—often due to the t(14;18) chromosomal translocation—leading to chemoresistance and tumor cell survival (PubMed: 15507153). As a therapeutic target, BCL2 mRNA is targeted by antisense oligonucleotides (ASOs) like oblimersen sodium (G3139), which are designed to bind to the initiation codon region of the mRNA (PubChem CID: 16135415). This hybridization triggers RNase H-mediated cleavage of the mRNA, effectively reducing the translation of the BCL-2 protein and sensitizing cancer cells to apoptosis-inducing therapies. While protein-level inhibitors like venetoclax are more clinically established, targeting the mRNA remains a significant strategy for modulating BCL-2 expression at the pre-translational level. The development of mRNA-targeting agents highlights the potential for precision medicine to address targets by intervening at the genetic message level.

Other names

BCL-2 mRNAB-cell CLL/lymphoma 2 mRNABCL2 transcriptBCL2 messenger RNABCL2

Antisense oligonucleotide-mediated degradation of mRNA via RNase H activation, preventing the translation of the anti-apoptotic BCL-2 protein (PubMed: 15507153).